JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB317882

PE Anti-Synapsin I antibody [EPR23531-50] – Synaptic Marker

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Synapsin I antibody - conjugated to PE. Synapse marker.

View Alternative Names

Synapsin-1, Brain protein 4.1, Synapsin I, SYN1

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Synapsin I antibody [EPR23531-50] - Synaptic Marker

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Synapsin I antibody [EPR23531-50] - Synaptic Marker

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Synapsin I - Synaptic Marker antibody [EPR23531-50]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Synapsin I - Synaptic Marker antibody [EPR23531-50]

  • 660 APC

    APC Anti-Synapsin I antibody [EPR23531-50] – Synaptic Marker

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Synapsin I antibody [EPR23531-50] - Synaptic Marker

  • Unconjugated

    Anti-Synapsin I antibody [EPR23531-50] - Synaptic Marker

  • Carrier free

    Anti-Synapsin I antibody [EPR23531-50] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23531-50

Isotype

IgG

Conjugation

PE

Excitation/Emission

Ex: 480;565nm, Em: 578nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Synapsin I also known as SYN1 plays an important role in synaptic function. It is a phosphoprotein with a molecular mass of approximately 78 kDa. Synapsin I is expressed mainly in the neurons of the central nervous system (CNS). It binds to synaptic vesicles and actin cytoskeleton which suggests that it functions in modulating neurotransmitter release at the presynaptic terminals. This modulation occurs as synapsin I undergoes phosphorylation which is critical for its activity.
Biological function summary

Synapsin I influences synaptic plasticity and is part of the synaptic vesicle trafficking complex. In its dephosphorylated state Synapsin I associates with synaptic vesicles anchoring them to the actin cytoskeleton. Upon phosphorylation Synapsin I changes conformation causing vesicles to mobilize. This activity supports the modulation of neurotransmitter release impacting learning and memory functions.

Pathways

Synapsin I participates significantly in the neurotransmitter release cycle and synaptic vesicle trafficking pathway. Protein kinase A (PKA) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulate its phosphorylation affecting how Synapsin I contributes to vesicle release. The phosphorylation of Synapsin I at sites such as serine 9 enables its interaction with other proteins like actin and spectrin facilitating vesicle movement.

Altered Synapsin I expression associates with neurological conditions like epilepsy and schizophrenia. In epilepsy dysregulation of Synapsin I phosphorylation processes can result in imbalanced neurotransmitter release potentially leading to seizures. Its connection to schizophrenia involves changes in synaptic plasticity which neurotransmitter systems such as dopamine and related proteins like alpha-synuclein also influence. Understanding these interactions can aid in developing therapeutic strategies.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Neuronal phosphoprotein that coats synaptic vesicles, and binds to the cytoskeleton. Acts as a regulator of synaptic vesicles trafficking, involved in the control of neurotransmitter release at the pre-synaptic terminal (PubMed : 21441247, PubMed : 23406870). Also involved in the regulation of axon outgrowth and synaptogenesis (By similarity). The complex formed with NOS1 and CAPON proteins is necessary for specific nitric-oxid functions at a presynaptic level (By similarity).
See full target information SYN1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com